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The purpose of the study was to determine toxicity, efficacy and immunologic effects of concurrent subcutaneous injections of low-
dose interleukin-2 (LD-IL-2), granulocyte–monocyte colony-stimulating factor (GM-CSF) and interferon-a 2b (IFNa) in progressive
metastatic renal cell carcinoma. In a multicentre phase II study, 59 evaluable patients received two to six cycles of subcutaneous IL-2
(4mIUm
 2), GM-CSF (2.5mgkg
 1) and IFNa (5mIUflat
 1) for 12 days per 3 weeks with evaluation after every two cycles. Cycles
were repeated in responding or stable patients. Data were analysed after a median of 30 months follow-up (range 16–48 months). In
42 patients, the immunologic response was studied and related to response and survival. The main toxicity were flu-like symptoms,
malaise and transient liver enzyme elevations, necessitating IL-2 reduction to 2mIUm
 2 in 29 patients, which should be considered
the maximal tolerable dose. The response was 24% (eight out of 34, three complete response (CR), five partial response (PR)) in
patients with metachronic metastases and 12% (three out of 25, 2CR, 1PR) in patients with synchronic metastases. Overall response
was 19% (11 out of 59). Median survival was 9.5 months. All tested patients showed expansion and/or activation of lymphocytes, T
cells and subsets, NK cells, eosinophils and monocytes. Pretreatment HLA-DR levels on monocytes and number of CD4
þHLA-DR
þ
cells correlated with response. Pretreatment number of CD4
þHLA-DR
þ cells and postimmunotherapy levels of lymphocytes,
CD3
þ, CD4
þ and CD8
þ T cells, but not of NK or B cells, correlated with prolonged survival. Immunotherapy with concurrent
subcutaneous GM-CSF, LD-IL-2 and IFNa has limited toxicity, can be given as outpatient treatment and can induce durable CR.
Response and survival with this form of immunotherapy seem to be more dependent on expansion/activation of T cells than of NK
cells.
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Metastatic renal cell carcinoma (mRCC) is insensitive to
chemotherapy and only moderately sensitive to radiotherapy. As
it is considered to be one of the most immunogenic tumours,
immunotherapy has been studied extensively (Bukowski, 1999;
Motzer et al, 2000). Currently, high-dose interleukin-2 (HD-IL-2)-
based immunotherapy seems most promising as treatment for
mRCC. Long-lasting complete responses (CRs) are induced in
5–10% of the patients (Fyfe et al, 1995; Bukowski, 1997; Negrier
et al, 1998). Unfortunately HD-IL-2 therapy is rather toxic,
requiring intensive care treatment in a considerable number of
patients. A less toxic treatment, generally used in Europe as single-
agent therapy, is subcutaneous (s.c.) interferon-a 2b (IFN-a)
(Fossa, 2000). The combination of HD-IL-2 and IFNa did not
induce more responses than either of the single-agent treatments
alone (Bukowski, 1997; Negrier et al, 1998).
The mechanism of action of HD-IL-2 therapy in mRCC is not
exactly known. The therapeutic effect can be exerted by either
activated T cells or activated NK cells. In mRCC patients several
immunologic defects have been described, comprising insufficient
antigen-presenting cell numbers, suppressed function of dendritic
cells (DCs) as well as T-cell function defects (Troy et al, 1998;
Bukowski, 1999).
We combined s.c. low-dose IL-2 (LD-IL-2) with IFNa and
granulocyte–monocyte colony-stimulating factor (GM-CSF) to
activate all limbs of the immune system and to avoid the toxicity
of intravenous (i.v.) HD-IL-2. These three cytokines together
stimulate all cells known to be involved in the induction of
antitumour responses: IL-2 stimulates T cells (Kolitz et al, 1987;
Thompson et al, 1988), IFNa induces better effector cell functions
and a higher expression of adhesion molecules and MHC class I on
tumour cells (Knop, 1990; Luft et al, 1998), while GM-CSF gives
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lproliferation and differentiation of DC (Ragnhammar, 1996).
Therefore, the combination may correct most defects in the
immune system.
After a phase I trial to determine the maximum tolerable dose
(MTD) of the combination of these cytokines (de Gast et al, 2000),
we started a multicentre phase II trial in the Netherlands with the
MTD. We here report the results of that phase II study in 63
patients receiving daily s.c. injections of LD-IL-2, IFNa and GM-
CSF for 12 days per 3 weeks. Apart from toxicity and efficacy, an
important part of the study was to determine activation and
expansion of immune cells in peripheral blood and to investigate
the correlation of these parameters with response to therapy and
survival.
PATIENTS AND METHODS
Patients
All patients entered into the trial, approved by the local ethical
committees, had biopsy or cytologic proven progressive mRCC
and had signed informed consent before therapy. Eligibility
criteria further included age above 18 years, WHO performance
score 0–2, ability to give informed consent, adequate bone
marrow function (leucocytes 44.0nl
 1, platelets 4100nl
 1) and
adequate renal (creatinine o180mmoll
 l) and liver function
(transaminases, alkaline phosphatase o3  upper limit of normal
(ULN), in case of liver metastases o5  ULN, normal bilirubin).
Exclusion criteria included serious cardiac, vascular, pulmonary
or metabolic disease, pregnancy or lactation, systemic immuno-
suppressive treatment, including systemic steroids, previous or
present autoimmune disease, aHIV antibodies and presence of
brain metastases unless solitary and removed. Previous immu-
notherapy with IFNa was allowed but had to be stopped at least 2
months before the start. Previous radiotherapy for bone metastasis
was allowed. Patients with only bone metastasis were excluded.
Characteristics of the 63 patients are listed in Table 1. In all, 38
patients had metachronic metastases (metastases that developed
some time after nephrectomy) and 25 patients had their primary
tumour still in situ at start of therapy (patients with synchronic
metastases). A majority of patients had lung metastases and two or
more sites of metastases.
Treatment
Low-dose interleukin-2 (Aldesleukin, Proleukin
R 4mIUm
 2,
Chiron BV Amsterdam, the Netherlands), GM-CSF (Molgramos-
tim, Leukomax
R 2.5mgkg
 1, provided by Schering-Plough, Maars-
sen, the Netherlands) and IFNa (Intron-A
R, 5mIU fixed dose,
Schering-Plough, Maarssen, the Netherlands) were given as daily
s.c. injections for 12 days in, respectively, abdominal wall, left leg
and right leg every day at different places. Immunotherapy was
initiated in the first cycle under controlled conditions in the
hospital and continued at home after 2–3 days when the drug
dosage was deemed safe for home administration. The remainder
of the first cycle and following cycles (every 3 weeks) was
completely given as outpatient treatment.
Dose modification
Interleukin-2 dose was reduced to 2mIUm
 2 if grade 4 fever with
hypotension, persistent severe malaise, diuretics insensitive weight
gain 45% or grade 3 liver enzyme elevations did occur.
Granulocyte–monocyte colony-stimulating factor had to be
reduced by 50% if allergic symptoms persisted despite adequate
treatment with antihistaminics. On the basis of leucocyte numbers
in the blood after 7 days, GM-CSF was stopped immediately (if
leucocytes 430nl
 1 on day 7), stopped after 9 days (if 25–
30nl
 1), or continued for the full 12 days (if o25nl
 1 on day 7) in
order to prevent excessive leucocytosis with eosinophilia. In case
of any grade 3 CTC toxicity except fever and flu-like syndrome,
medication had to be interrupted until resolution of that toxicity
and the most probable causative agent reduced to 50% in the next
cycle.
Supportive measures
Prior to the start of immunotherapy, patients received 1
2 lo f
saline (NaCl 0.9%) intravenously and during immunotherapy
Acetaminophen 1g with the injections, 1g at the start of chills and
500mg tablets if necessary to a maximum of 4g per 24h.
Metoclopramide was used to treat or prevent nausea. No systemic
steroids were allowed unless absolutely necessary and NSAIDs
were avoided in order not to suppress macrophage function.
Evaluations
Prior to treatment, intravenous contrast enhanced computer
tomography (CT) scans of chest, abdomen and pelvis were made,
magnetic resonance imaging (MRI) of the brain and radioactive
technetium scan of the bone was performed in addition to physical
examination (PE) to determine the extent of the disease. In
addition, an electrocardiogram and blood tests for haematology,
liver and renal function and an HIV antibody test were performed.
Complete blood counts, differential WBC count, platelet count,
liver and renal function tests were performed at start of treatment,
after 1 week and at the end of immunotherapy (after 12 days) and
after 3 weeks (before the next cycle). In addition, the absolute
numbers of T cells (CD3, CD4, CD8), NK cells (CD3-CD16þ56þ),
monocytes (CD14þ) and B cells (CD19þ) and of the activated
cells (double staining with HLA-DR) were determined before
treatment, at day 12 and day 23 with monoclonal antibodies on the
FACS scan flow cytometer as described before (de Gast et al, 2000).
Soluble IL2-receptor (sIL2R, Eurogenetics, Tessenderlo, Belgium)
and sCD8 (T cell Diagnostics, Cambridge MA, USA) were assayed
by ELISA as described before (de Gast et al, 2000).
Response evaluation
Physical examination, CT scans and MRI of the brain were
repeated after two cycles in week 7. Metastatic disease was
Table 1 Characteristics of the 63 eligible patients
Age (years)
Median 58
Range 31–75
WHO performance status
03 6
12 3
24
Male/female 44/19
Synchronic metastases 25
Metachronic metastases 38
Sites of disease
Soft tissue only 3
Lung metastasis (7soft tissue) 36
Bone+others organs 19
Liver7other organs 9
Adrenal7lung 2
No. of metastatic sites
12 3
22 5
421 5
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lquantified as the sum of products of perpendicular diameters of
marker lesions. All measurable lesions on CT scans were used as
marker lesions and up to 10 subcutaneous nodules were used as
such. Responses were defined as CR: disappearance of all
measurable disease; as partial response (PR): 50% or more
reduction in measurable disease with no new lesions; as stable
disease (SD): less than 25% increase or less than 50% decrease in
measurable disease and no new lesions; or as progressive disease
(PD): 25% or more increase in measurable disease or the
appearance of new lesions, or nonreturn for evaluation because
of deteriorating clinical condition. Responses must have been
confirmed by another post-treatment evaluation 6 weeks later.
In case of PD, immunotherapy was stopped and palliative
radiotherapy considered. In case of SD, another two cycles were
given. In patients with regression, cycles were continued with a
response evaluation after every two cycles. If CR was reached, two
consolidation cycles were given. In patients with the primary
tumour in situ, nephrectomy was performed and cycles with
immunotherapy given within 6 weeks after recovery with response
evaluation after every 2 cycles.
Statistics
Survival curves were constructed using the Kaplan–Meier
technique using the initiation of immunotherapy as starting point.
Levels of circulating cells in peripheral blood and of cytokines,
at various time points and in various groups, were compared by
Student’s t-test. P-values o0.05 were considered significant.
RESULTS
Patients
In all, 63 patients started treatment. Four patients stopped
treatment within 7 days because of rapidly PD (2), hypercalcaemia
(1) or cardiac arrhythmia and decompensation (1). As shown in
Table 2, eight of the 34 evaluable patients with metachronic
metastases achieved remission (24%, three CR, five PR) and 13
showed SD (38%). Four patients received IFNa for metastatic
disease prior to treatment with concurrent immunotherapy. In two
patients, a SD was reached, but no responses were seen. One CR
patient relapsed in the bone after 8 months and died after 31
months. The two other CR patients are both in continued
remission for 40þ months. One patient with an isolated lung
metastasis after two cycles underwent a lobectomy and achieved a
surgical CR, now maintained for 12þ months.
Of the 25 patients with synchronic metastases, only 14 under-
went nephrectomy and 11 patients underwent no nephrectomy,
because of rapidly progressive disease (Table 2). Two patients
achieved CR after nephrectomy, of whom one got a relapse of his
lung and pleural lesions after 4 months and one is still in
continued CR for 15þ months. One patient with lung and adrenal
metastasis achieved a PR. The response rate in the whole group
was 11 out of 59 (19%) with five CR and six PR. Three of the five
CR patients are in maintained remission (15þ,4 0 þ,4 0 þ
months). Survival of all patients entering the study (n¼63) is
shown in Figure 1.
Toxicity
All patients developed flu-like symptoms with fever, chills, malaise
and anorexia, which was only partly alleviated by Acetaminophen
(Table 3). Interleukin-2 was reduced to 2mIUm
 2 in eight patients
with grade 4 fever with hypotension on the first day. As a result of
persistent fatigue grade 3, IL-2 was reduced in another 15 patients
after 1 week. In addition, IL-2 was reduced in the second cycle
because of grade 3 liver function disturbances (only enzyme
elevations) in five patients and because of grade 3 creatinine
elevation in one. So in total, IL-2 was reduced from 4 to 2mIUm
 2
in 29 out of 59 patients, who received at least 1 full cycle of
combined immunotherapy. A further reduction to 1mIUm
 2 of
IL-2 was necessary in two patients because of persistent grade 3
fatigue. Allergic reactions grade 3 (angioedema) occurred in two
patients, rapidly reacting to antiallergics and stopping of GM-CSF.
One patient had cardiac arrhythmia and decompensation after 3
days, necessitating stopping of all treatment.
Leucocytosis with eosinophilia was seen in all patients during
immunotherapy (median 22nl
 1, range 15–37nl
 1). Granulo-
cyte–monocyte colony-stimulating factor was stopped because of
excessive leucocytosis in only two patients.
None of the patients died of treatment-related toxicity or needed
hospital admission.
Immunologic evaluation
From all patients treated in the Antoni van Leeuwenhoek Hospital,
Amsterdam (n¼42) blood samples were taken during and after
therapy to assess the effects of combined immunotherapy on
immunologic parameters in peripheral blood. The parameters that
were tested were lineage markers for T cells, B cells, NK cells and
monocytes and number of eosinophils. To test the activation
status, concomitant HLA-DR expression on lymphocytes and
Table 2 Response evaluation
No. of patients
Synchronic metastases
Response
Metachronic
metastases With Nx
a Without Nx Total
CR
PR
3
5

8ð24%Þ
2
1
0
0

3ð12%Þ
5
6

11ð19%Þ
SD 13 (1sCR) 9 0 22
PD 13 2 11 26
34 14 11 59
aNx¼nephrectomy, CR¼complete remission; PR¼partial remission; SD¼stable
disease; PD¼progressive disease, sCR¼surgical CR.
Kaplan_Meier survival estimate 
0 5  10  15  20 25 30 35 40 45 
Survival from registration (months) – 63 patients 
1.00
0.75
0.50
0.25
0.00
Figure 1 Median survival for all 63 registered patients was 9.5 months.
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lmonocytes and sIL-2R and sCD8 levels in serum were examined.
All markers, except the number of B cells, showed a significant
increase on day þ12 of therapy (Figure 2 and data not shown). At
11 days after cessation of the therapy most markers had returned
to baseline values. In order to identify prognostic markers, patients
with a response (CR/PR), SD or PD were studied for all the
parameters. In Table 4, the most relevant data are shown. The
values of the patients with SD were generally found to be
intermediate between the values of responders and PD patients.
No significantly different markers were found for the CR/PR group
vs the SD group as well as for the SD group vs the PD group.
However, when the values of patients with CR/PR before
immunotherapy were compared to those with PD, the responders
had significantly higher numbers of activated CD4T cells, but not
of total numbers of CD4T or (activated) CD8þ T in their
peripheral blood before immunotherapy. Furthermore, the ex-
pression level of HLA-DR on monocytes was significantly higher in
patients with CR/PR than in patients with PD. In contrast, the total
number of monocytes did not differ between the two groups.
The patients monitored for immunologic markers were also
stratified into two survival groups, based on the median survival: a
prolonged survival group (survival 10 months or longer) and a
short survival group (survival less than 10 months). As expected,
the number of responders (seven out of 20) and SD patients (11
out of 20) was higher among the patients with prolonged survival
than among the patients with short survival (one out of 22
responder and seven out of 22 SD). Only one prognostic marker
was found when the pretreatment values were compared with
survival. As shown in Table 5, a significantly higher number of
activated CD4T cells was found in the prolonged survival group
compared to the short survival group. Furthermore, comparing the
values at the end of immunotherapy (day 12), five more markers
were found. Total number of lymphocytes, of CD3, CD4 and CD8T
cells and levels of sIL-2R, but not of NK cells or levels of sCD8,
correlated with survival.
DISCUSSION
As RCC is known for its resistance against chemotherapy and for
its immunogenic properties, cytokines have been used with various
successes to treat this disease. The cytokines used in the current
immunotherapy protocol, LD-IL-2, IFNa and GM-CSF, have been
reported to induce antitumour activity to a greater or lesser extent
(Sarna et al, 1987; Figlin et al, 1988; Vogelzang et al, 1993; Schiller
et al, 1996; Bukowski, 2000; Fossa, 2000; Westermann et al, 2001).
The combination of these three cytokines given simultaneously is
based on the idea that expansion and activation of antigen-
presenting cells (by GM-CSF), T cells (LD-IL-2 and GM-CSF) and
effector cells (by LD-IL-2, GM-CSF, IFN-a), as well as an increase
in immunosensitivity of the tumour cells (by IFN-a) is required
for an optimal effect. Concurrent immunotherapy consisted of
daily s.c. injections of 4mIUm
 2 IL-2, 2.5mgkg
 1 GM-CSF
and 5mIU fixed dose IFN-a for 12 days per 3 weeks, a dose
determined as the MTD in a phase I study (de Gast et al, 2000).
However, in this phase II study IL-2 reduction to 2mIUm
 2 was
necessary in 29 of the 59 patients because of grade 4 fever with
hypotension (eight), severe fatigue (15), grade 3 liver enzyme
elevations (five) or grade 3 renal function impairment (one).
Therefore, we have to conclude that the MTD of this combination
is IL-2 2mIUm
 2, GM-CSF 2.5mgkg
 1 and IFNa 5mIU fixed dose.
With the lower dose of IL-2 outpatient treatment was possible
without treatment-related mortality or hospital admission. In all,
59 evaluable patients showed an overall response rate of 19%, with
Table 3 Toxicity (NCI-CTC 2.0)
Grade 2 Grade 3 Grade 4
1. Fever/chills 47 8 8
2. Fatigue 40 15 0
3. Liver function 9 5 0
4. Renal function 12 1 0
5. Allergic reactions 5 2 0
6. Cardiovascular 0 1 0
7. Haemoglobin 6 0 0
8. Platelets 0 0 0
9. Granulocytes 0 0 0
Table 4 Immunologic evaluation and response
Cell type pre
a Responders SD PD Resp. vs PD
CD4
+DR
+ 111732
b 113740 5778 P¼0.05
CD4 8707169 658747 696798 NS
CD8
+DR
+ 2087123 76710 52716 NS
CD8 6257301 236722 215734 NS
CD14 734793 791780 780772 NS
HLA-DR level
on monocytes
10597167 722784 556777 P¼0.01
aCell type pre¼cell type before immunotherapy;
bCellsnl
 1 in peripheral blood,
mean7s.e.; SD¼stable disease, PD¼progressive disease, yDR
+¼double fluor-
escence with HLA-DR, NS¼nonsignificant P-value.
Table 5 Immunologic evaluation and survival
Long survival
(n¼20)
Short survival
(n¼22) P-value
CD4
+DR
+ Pre
a 130734
b 5678 P¼0.05
Lymphocytes Post 26897374 17777122 P¼0.02
CD3 Post 18977350 12157119 P¼0.04
CD4 Post 10587132 652782 P¼0.01
CD8 Post 6067190 249731 P¼0.03
NK Post 459769 359753 NS
sIL-2R
c Post 1504972323 944771170 P¼0.05
sCD8
c Post 8897155 641792 NS
aPre¼pretreatment,
bcellsnl
 1 in peripheral blood; mean7s.e.;
carbitrary ELISA
units, NS¼nonsignificant P-value.
Immune response during therapy
0
1000
2000
3000
Pretreatment d+12 d+23
CD3
CD4
CD3+HLA-DR+
NK
CD8
B
Figure 2 The number of T cells (CD3), activated T cells (CD3/DR), T
helper cells (CD4), cytotoxic T cells (CD8) and of NK cells showed a
significant increase after 12 days of immunotherapy, but not the number of
B cells (CD19).
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l9% CR, 10% PR, 38% SD and 43% PD, which seems to be not
different from HD-IL2 and maybe superior to IFN-a treatment
concerning response.
In two recently published trials (Flanigan et al, 2001; Mickisch
et al, 2001) nephrectomy followed by immunotherapy was found
to be superior to immunotherapy alone with IFN-a with respect to
survival in patients with synchronic metastases. In our series only
12 out of 25 patients with synchronic metastasis had a
nephrectomy because of rapidly PD in the other 13 patients.
High-dose interleukin-2 therapy can elicit serious NK cell-
mediated toxicity, necessitating intensive care treatment and
causing up to 4% treatment-related mortality. In two larger studies
(Fyfe et al, 1995; Negrier et al, 2000), an objective response rate of
15–19% was found, with 5 and 6% CRs, respectively. Of the
complete responders, 75% remained disease free after 3 years.
With our study, we aimed to develop a better tolerated treatment
than HD-IL-2 i.v., which can be given as outpatient treatment and
has a similar response rate. Response rate, percentage of durable
CRs (three out of 59¼5%) and survival seem not to be different
from HD-IL-2 treatment, but tolerability seems better and our
treatment could be given as outpatient treatment. However, a
phase III study would be necessary to prove therapeutic
equivalence.
Although we intended to activate and expand T cells and not NK
cells with a low dose of IL-2 (and GM-CSF) to avoid toxicity, we
found in all patients an increase in number and activation status of
all lymphocytes tested, including NK cells, with the exception of B
cells. As no vascular leak syndrome, because of excessive NK cell
activation, was observed in any of the patient, the IL-2 dose was
not too high. Two markers appeared to correlate with response.
Both activated CD4 helper T cells (CD4
þHLA-DR
þ) and HLA-DR
levels on monocytes demonstrated a significant difference between
responders and those with PD. Strikingly, neither CD8 cytotoxic T
cell nor monocyte numbers showed a correlation with response. It
is tempting to speculate that antigen-presenting cells and helper T
cells that were already activated in some patients contributed to
the response seen in these patients.
A more important aspect of the study was the measurement of
activation of immune cells and its relation to survival. To evaluate
the effect on survival, patients were divided into those with
prolonged survival (X10 months) and those with short survival
(o 10 months). Again, activated CD4 helper T cells were found to
predict prolonged survival in the pretreatment values. Evaluating
the values after 12 days of therapy, five other markers showed a
significant difference between the two groups: total lymphocytes,
total T cells (CD3
þ), CD4
þ helper T cells, CD8
þ cytotoxic T cells
and sIL-2R. No correlation with NK cells was seen in either
response or survival groups, indicating that the effects of
combined immunotherapy are not NK cell, but T cell and
monocyte mediated.
Our trial is the first in which markers for response and survival
of IL-2-based therapies are reported for mRCC. In a study reported
by Westermann et al (2001), IL-2 and IFN-a were added
sequentially to GM-CSF in doses comparable to our scheme.
Although they also found a general increase in lymphocytes, the
number of treated patients was too small to distinguish between
responder groups. In a trial with LD-IL-2 i.v., 25 patients were
treated and no correlation with response could be found for any of
the lymphocyte populations tested (Favrot et al, 1990). In several
other studies in which the combination of IL-2 and IFN-a was
used, the trials were too small to determine a correlation with
response to treatment (Bukowski, 1997). However, in a large trial
with HD-IL-2 therapy for metastatic melanoma, responding
patients were found to have a significant higher maximum
lymphocyte count immediately after therapy (Phan et al, 2001).
Notably, in that trial only total lymphocyte numbers were
determined and no differentiation was made between T-cell and
NK-cell numbers. This indicates that patients responding to
immunotherapy may be identified by analysis of peripheral
blood samples. The correlation between immunological
markers and survival should first be confirmed in a prospective
study. As our series was limited, a multivariate analysis was not
possible to study whether the immune parameters added anything
over the use of known clinical parameters determining the
presence of low, intermediate or high risk for survival (Zisman
et al, 2002).
Immunotherapy protocols are thought to be most effective if
smaller amounts of tumour are present, as indicated by the patient
groups that respond best to cytokine immunotherapy, for example,
good performance status, prior nephrectomy, lung metastases
only, few metastatic sites (Mani et al, 1995). This might indicate
that this protocol could be more effective in a perioperative setting
in which nearly all tumour can be removed. In a perioperative
immunotherapy protocol, it is also possible to look at the effects of
immunotherapy at the site of the tumour and to relate those results
with the effects in peripheral blood. Especially the activation and
attraction to the tumour site of DCs and T cells, in relation to the
effects on peripheral blood, may give important insight into the
kinetics of cells of the immune system. Such a trial, which is
currently ongoing in our hospital, may give us more under-
standing in how the antitumor effect is achieved and may enable us
to further improve upon cytokine immunotherapy.
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